# Computational Structural Comparison of Toxoplasma gondii CDPK1 and Human BUB1 kinases: Implications for Selective Inhibitor Design

## TL;DR

Researchers compared two kinases from a parasite and humans to design drugs that target the parasite without affecting human cells.

## Contribution

The study reveals structural similarities and differences between TgCDPK1 and BUB1 kinases, enabling selective inhibitor design.

## Key findings

- TgCDPK1 and BUB1 share a glycine gatekeeper but differ in electrostatic and structural properties.
- Molecular dynamics show TgCDPK1 has more focused interaction networks than BUB1.
- Virtual screening confirms stronger inhibitor binding to TgCDPK1 over BUB1.

## Abstract

Toxoplasmosis, affecting one-third of the global human population, urgently requires new therapeutic strategies
due to current treatment limitations and drug resistance. Toxoplasma gondii calcium-dependent protein kinase
1 (TgCDPK1) is a promising drug target due to its essential role in
parasite survival and its presumed unique glycine gatekeeper residue.
Aiming at identifying new and selective inhibitors of TgCDPK1, we
performed computational structural analyses and unexpectedly found
that a human kinase (BUB1), despite having only 14% sequence identity, shares
this glycine gatekeeper with TgCDPK1, which initially raised concerns
for selective inhibitor development. Subsequent analyses revealed
distinct electrostatic properties and binding site architectures between
these kinases. Molecular dynamics simulations demonstrate differential
binding pocket dynamics, with TgCDPK1 showing more focused interaction
networks compared to BUB1’s dispersed patterns. Virtual screening
of apicomplexan kinase inhibitors confirms stronger binding affinity
for TgCDPK1 over BUB1, supporting the continued development of selective
therapeutics against toxoplasmosis.